Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company focuses on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. It is in business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The company was founded by Roger S. Newton and Charles L. Bisgaier on January 22, 2008 and is headquartered in Ann Arbor, MI.
